Press Releases

All Releases
Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain
Feb 25, 2015
PDF 18.4 KB
Nektar Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results
Feb 24, 2015
PDF 26.2 KB
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2014 on Tuesday, February 24, 2015, After Close of U.S.-Based Financial Markets
Feb 17, 2015
PDF 10.7 KB
Baxter Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A
Feb 11, 2015
PDF 61.9 KB
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Jan 6, 2015
PDF 8.9 KB
Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of Etirinotecan Pegol (NKTR-102) in Patients with Advanced Breast Cancer
Dec 11, 2014
PDF 17.5 KB
MOVENTIG® Approved In The European Union For Opioid-Induced Constipation
Dec 9, 2014
PDF 10.3 KB
Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A
Dec 1, 2014
PDF 60.3 KB
Nektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a PARP Inhibitor in BRCA1-deficient Cancer Model
Nov 20, 2014
PDF 13.7 KB
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2014
Nov 6, 2014
PDF 28.2 KB
Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets
Oct 30, 2014
PDF 7.7 KB
Nektar Therapeutics Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation
Sep 26, 2014
PDF 12.3 KB
Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting
Sep 19, 2014
PDF 11.4 KB
FDA approves MOVANTIK™ (naloxegol) Tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain
Sep 16, 2014
 
Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients
Aug 21, 2014
PDF 12.3 KB
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Jul 31, 2014
PDF 27.0 KB
Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
Jul 22, 2014
PDF 7.7 KB
Data Published in the New England Journal of Medicine Demonstrate that Naloxegol Improved Opioid-Induced Constipation in Chronic Pain Patients
Jun 19, 2014
PDF 15.6 KB
US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK
Jun 12, 2014
PDF 13.7 KB
Nektar Therapeutics Stock Trading Halted Today; FDA Advisory Committee to Discuss Peripherally-Acting Opioid Receptor Antagonists
Jun 11, 2014
PDF 11.1 KB
Showing 1-20 of 210 Page: 1 2 3 ... 11  Next 20
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide